MedTrace Logo

Cross-sectional Area of Pubovisceral Muscle in Nulliparous and Primiparous Women

NCT05800678 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-07-27

No results posted yet for this study

Summary

Pelvic-floor disorders (PFD), including pelvic organ prolapse, urinary and fecal incontinence, decrease quality of life of every fourth women. 1 The main known risk factor for PFD is vaginal delivery 2,3 causing pelvic floor muscle avulsion, ischemia or denervation.4 Ultrasound (US) and magnetic resonance imaging (MRI) are frequently used to investigate structural changes in pelvic floor muscles. The investigators aimed to focus on structural changes (atrophy) caused by muscle denervation. 5 The pubovisceral muscle (PVM) is the part of the levator ani muscle (LAM) which is most frequently injured and it is thought to be possibly denervated by overstretching 6 Recently, the most precise measurement of PVM cross-sectional area was performed by the group of DeLancey. 7 In our study, the investigators aimed to describe which are the normal values of PVM volume in nulliparous women. The investigators performed a measurement of PVM volume in women after the first vaginal delivery.

The investigators hypothesized that there will be a decrease of the cross-sectional area of the PVM developed after denervation trauma.

Conditions

  • Pelvic Floor Disorders

Sponsors & Collaborators

  • Institute for the Care of Mother and Child, Prague, Czech Republic

    lead OTHER

Principal Investigators

  • Lucie Hájková Hympánová, PhD · Ústav pro péči o matku a dítě, Praha, CZ

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-03-23
Completion
2023-03-23

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05800678 on ClinicalTrials.gov